Tuesday, August 16, 2022
    HomeHealthJPM22 in review, Biogen's worsening fortunes, & RNA drugs' future

    JPM22 in review, Biogen’s worsening fortunes, & RNA drugs’ future


    Was J.P. Morgan a drag? Is it time to surrender on Aduhelm? And what number of guitars is just too many?

    We cowl all that and extra this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT well being tech correspondent Katie Palmer joins us to recap the J.P. Morgan Healthcare Convention. Then, we focus on the newest twist in Biogen’s quest to increase the usage of Aduhelm and what it means for the therapy of Alzheimer’s illness. Lastly, Arrakis Therapeutics CEO Michael Gilman calls in to clarify how concentrating on RNA can deal with illness and why the characters in “Dune” don’t simply shoot one another with laser weapons.

    For extra on what we cowl, right here’s a look at J.P. Morgan; right here’s the latest on Aduhelm; right here’s more on Arrakis; right here’s where you can subscribe to the First Opinion Podcast; and right here’s our complete coverage of the Covid-19 pandemic.


    Make sure you join on Apple PodcastsStitcherGoogle Play, or wherever you get your podcasts.

    And you probably have any suggestions for us — matters to cowl, visitors to ask, vocal tics to stop — you’ll be able to e-mail [email protected].


    All in favour of sponsoring a future episode of “The Readout LOUD”? E mail us at [email protected].

    Source link

    Related articles

    Stay Connected


    Latest posts